Healthcare systems have historically generated the overwhelming majority of clinical data episodically. A patient feels a symptom, schedules a doctor appointment, undergoes a targeted blood test or imaging scan, and receives a prescription. Between those rare, sickness-driven encounters, the human body remains largely unobserved, leaving the electronic health record (EHR) as a fragmented ledger of past illness rather than a continuous map of living biology.

That paradigm is now facing an unprecedented capital mobilization.

On September 24, Neko Health opens its first United States clinic in New York City with more than 25,000 people on its waitlist, backed by a recent $700 million Series C led by Lightspeed Venture Partners and O.G. Venture Partners that pushed total disclosed funding above $1 billion. Co-founded by Spotify chief executive Daniel Ek and CEO Hjalmar Nilsonne, Neko pairs custom 3D optical body mapping and cardiovascular pulse-wave sensors with blood biomarker analysis and on-site physician consultations.

Neko is part of a much larger structural convergence. Function Health has scaled past 500,000 active members paying $365 annually for 160+ longitudinal lab tests backed by a $450 million growth financing facility, while smart-ring maker Oura disclosed in its September 3 SEC S-1 filing that it generated $1.2 billion in revenue in the first nine months of 2026 at a 74% year-over-year growth rate.

These companies are not merely selling standalone scans or blood panels. They are competing to build the longitudinal baseline health record that exists before disease becomes symptomatic.

In this deep dive, we map the emerging pre-symptomatic care ecosystem:

In this deep dive, we are going to look at:

  • Why this matters now
  • What actually happened in the market
  • The obvious read versus the deeper signal
  • The pre-symptomatic market map: From continuous wearables to full-body imaging
  • The clinical dilemma: Incidental findings, overdiagnosis, and the cascade effect
  • The Evidence Ladder: What early screening proves versus where attribution remains unverified
  • The economic transition: Cash-pay early adopters versus scalable employer coverage
  • The international lesson: What Estonia's biobank teaches us about risk-stratified screening
  • The HealthTech Investor's Signal: Capital allocation, multiple compression, and platform defensibility
  • Four concrete milestones to watch over the next 12 to 24 months
  • The bottom line for health system leaders and technology investors